Risk of out-of-hospital cardiac arrest in antidepressant drug users

Br J Clin Pharmacol. 2022 Jul;88(7):3162-3171. doi: 10.1111/bcp.15224. Epub 2022 Feb 7.

Abstract

Conflicting results have been reported regarding the association between antidepressant use and out-of-hospital cardiac arrest (OHCA) risk. We investigated whether the use of antidepressants is associated with OHCA.

Methods: We conducted a nationwide nested case-control study to assess the association of individual antidepressant drugs within drug classes with the hazard of OHCA. Cases were defined as OHCA from presumed cardiac causes. Cox regression with time-dependent exposure and time-dependent covariates was conducted to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs) overall and in subgroups defined by established cardiac disease and cardiovascular risk factors. Also, we studied antidepressants with and without sodium channel blocking or potassium channel blocking properties separately.

Results: During the study period from 2001 to 2015 we observed 10 987 OHCA cases, and found increased OHCA rate for high-dose citalopram (>20 mg) and high-dose escitalopram (>10 mg; HR:1.46 [95% CI:1.27-1.69], HR:1.43 [95% CI:1.16-1.75], respectively) among selective serotonin reuptake inhibitors (reference drug sertraline), and for high-dose mirtazapine (>30; HR:1.59 [95% CI:1.18-2.14]) among the serotonin-norepinephrine reuptake inhibitors or noradrenergic and specific serotonergic antidepressants (reference drug duloxetine). Among tricyclic antidepressants (reference drug amitriptyline), no drug was associated with significantly increased OHCA rate. Increased OHCA rate was found for antidepressants with known potassium channel blocking properties (HR:1.14 [95% CI:1.05-1.23]), but for not those with sodium channel blocking properties. Citalopram, although not statistically significant, and mirtazapine were associated with increased OHCA rate in patients without cardiac disease and cardiovascular risk factors.

Conclusion: Our findings indicate that careful titration of citalopram, escitalopram and mirtazapine dose may have to be considered due to drug safety issues.

Keywords: antidepressants; depolarization-blocking drugs; sudden cardiac arrest.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / adverse effects
  • Case-Control Studies
  • Citalopram* / adverse effects
  • Humans
  • Mirtazapine / adverse effects
  • Norepinephrine
  • Out-of-Hospital Cardiac Arrest* / chemically induced
  • Out-of-Hospital Cardiac Arrest* / epidemiology
  • Potassium Channels
  • Selective Serotonin Reuptake Inhibitors / adverse effects

Substances

  • Antidepressive Agents
  • Potassium Channels
  • Serotonin Uptake Inhibitors
  • Citalopram
  • Mirtazapine
  • Norepinephrine